MyMD Pharmaceuticals, Inc. Overview
Pro stress-test →MyMD Pharmaceuticals is a clinical stage pharmaceutical company committed to extending healthy lifespan, focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing symptoms. The company is developing groundbreaking therapies for serious autoimmune and inflammatory diseases, with MYMD-1 as its lead clinical candidate—an orally available next-generation TNF-α inhibitor with the potential to transform TNF-α based disease treatment.
Strategic Profile
Pro stress-test →MYMD-1 is distinguished as a first-in-class oral treatment shown to reduce TNF-α and inflammation without infusion or injection, with an advantage over currently available TNF-α blockers, none of which are dosed orally. The company's second platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy as a novel synthetic derivative of cannabidiol addressing the growing CBD market.
Competitive Landscape
Pro stress-test →MyMD competes in the TNF-α inhibitor space against established players like Amgen, Janssen, and Eli Lilly who offer infusion/injection-based therapies. The company's oral formulation represents differentiation. In the CBD therapeutic space, competition includes GW Pharmaceuticals (Epidiolex) and emerging synthetic CBD developers. The landscape is characterized by significant unmet needs in autoimmune diseases and age-related conditions.
Industry Context
MyMD Pharmaceuticals, Inc. operates in Clinical-stage biopharmaceuticals (TNF-α inhibitors and CBD therapeutics).
Key facts
Founded: 2014 · Headquarters: Baltimore, US · Employees: 9